AAS
NKTR icon

Avantax Advisory Services’s Nektar Therapeutics NKTR Stock Holding History

Avantax Advisory Services’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-922
Closed -$238K – 1210
2021
Q2 		$238K Sell
922
-17
-2% -$4.71K ﹤0.01% 999
2021
Q1 		$282K Buy
+939
New +$292K 0.01% 831
2020
Q4 		– Sell
-1,504
Closed -$372K – 1209
2020
Q3 		$372K Buy
+1,504
New +$473K 0.01% 925

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Avantax Advisory Services's NKTR Position: Q3 2021 in Review

Avantax Advisory Services sold out of Nektar Therapeutics (NKTR) in Q3 2021, closing a stake of 922 shares — an estimated $238K sold.

Avantax Advisory Services first reported a position in NKTR in Q3 2020 and held it in 3 quarters. The position peaked at $372K in Q3 2020. 240 funds tracked by Wall St. Rank hold NKTR as of Q3 2021.

  • Avantax Advisory Services reported no remaining Nektar Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Avantax Advisory Services sold 922 Nektar Therapeutics shares in Q3 2021, an estimated $238K.
  • Avantax Advisory Services first reported a position in Nektar Therapeutics in Q3 2020 and held it in 3 quarters.
  • Avantax Advisory Services's Nektar Therapeutics position peaked at $372K in Q3 2020.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2021.

Based on Avantax Advisory Services's 13F filing for Q3 2021, filed 21 Oct 2021.